+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07381764

ROMANCE GOIM Trial Comparing Irinotecan Plus Cetuximab Rechallenge Versus TrifluridineTipiracil Plus Bevacizumab for Molecularly Selected Metastatic Colorectal Cancer

Led by Gruppo Oncologico Italia Meridionale · Updated on 2026-09-11

150

Participants Needed

26

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two treatment options for patients with metastatic colorectal cancer whose disease has worsened after standard therapies. This phase II, open-label, multicenter clinical trial compares a rechallenge treatment using irinotecan plus cetuximab to the current standard of care, trifluridinetipiracil plus bevacizumab, as third-line therapy. Patients are selected based on specific molecular features of their cancer identified through circulating tumor DNA analysis from a blood sample. The main goal is to see if the rechallenge treatment results in a higher tumor response rate compared with the standard therapy. Participants are randomly assigned to one of two groups. The experimental group receives cetuximab combined with irinotecan administered every two weeks. The control group receives oral trifluridinetipiracil on a cycle of 28 days along with bevacizumab every two weeks. Treatment continues until the disease worsens, side effects become unacceptable, or the participant chooses to stop. Tumor response is regularly checked using CT or MRI scans following RECIST criteria. After disease progression, switching to the other treatment may be considered. During the trial, participants undergo scheduled tumor assessments, safety and tolerability monitoring, and quality of life questionnaires. Adverse events are tracked from the first dose until 30 days after the last dose. The study measures objective response rate primarily, as well as progression-free survival, overall survival, treatment exposure, and quality of life over up to 36 months. Long-term follow-up will assess survival outcomes, with treatments given under medical supervision until progression or withdrawal.

CONDITIONS

Brief Title

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

Research Team

D

Davide Ciardiello DC Principal Investigator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here